© F e r r a t a S t o r t i F o u n d a t i o nThe purpose of the present retrospective study was to investigate whether the predictive value of pre-transplant levels of parameters representing endothelial cell function, such as angiopoietin-2, could be further refined by measuring pre-transplant nitrate levels, and to analyze whether negative influences on clinical outcome could be attenuated by (potentially endothelium-protective) concomitant statin administration.
Methods
Eligibility of patientsPatients were eligible for this study if they had undergone allogeneic SCT at our institution between June 2002 and December 2011 and their blood samples were available for nitrate measurement (collected directly before the start of conditioning chemotherapy prior to allogeneic SCT). Written informed consent to sample and data collection in accordance with to the declaration of Helsinki was obtained from all eligible patients as well as normal donors (n=49) and sample and data collection was approved by the responsible Institutional Review Board.
Graft-versus-host disease prophylaxis, treatment, and supportive careGVHD prophylaxis was performed as previously described 2,3 and remained unchanged over the whole study period. GVHD was clinically and histologically diagnosed and graded using standard criteria.24 Steroid-refractory GVHD was defined as histologically confirmed disease not responding to standard prednisone therapy (2x1 mg/kg body weight, for intestinal GVHD combined with mycophenolate mofetil 2x1 g/day) and requiring second-line salvage immunosuppressive therapy which was generally pentostatin 25 (see Online Supplementary Methods).
Enzyme-linked immunosorbent assays, multiplex analyses, nitrate assay and western blotsSerum levels of angiopoietin-2 were quantified by multiplex protein array technology in 327 patients as reported before.3 TNF levels were measured in 417 patients by enzyme-linked immunosorbent assay (BD Biosciences Pharmingen, San Diego, CA, USA). Serum nitrates (n=417 samples) were determined using the Griess Reagent System (see Online Supplementary Methods).The following monoclonal antibodies were used for the western blots: rabbit anti-TNF-α (Cell Signaling Technology through New England Biolabs, Frankfurt, Germany), mouse anti-iNOS (2D2-B2) (R&D Systems, Wiesbaden-Nordenstadt, Germany) and mouse anti-β-actin (AC-15) (Abcam, Cambridge, UK). Corresponding secondary antibodies were purchased from SigmaAldrich (Deisenhofen, Germany).
Statistical analysisCategorical and continuous variables of the patients' characteristics were compared using the Fisher exact test and the MannWhitney test, respectively. Cumulative incidences of refractory GVHD were compared using the log-rank test. The choice of cutoffs for nitrates and angiopoietin-2 is explained in the Online Supplementary Methods.Non-relapse mortality (NRM) was calculated as the time from allogeneic SCT to death in the absence of relapse, considering recurrence of the underlying malignancy as a competing event. the NRM rates of differ...